HC Wainwright Has Negative Forecast for RMTI Q2 Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – Stock analysts at HC Wainwright dropped their Q2 2026 earnings estimates for Rockwell Medical in a research note issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.02) for the quarter, down from their prior forecast of ($0.01). HC Wainwright currently has a “Buy” rating and a $2.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.05) EPS.

A number of other research firms have also commented on RMTI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rockwell Medical in a research report on Thursday, January 22nd. Wall Street Zen upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $2.00.

Rockwell Medical Stock Performance

RMTI stock opened at $0.96 on Wednesday. Rockwell Medical has a 1-year low of $0.78 and a 1-year high of $2.10. The company has a current ratio of 3.98, a quick ratio of 3.63 and a debt-to-equity ratio of 0.25. The firm has a market cap of $37.70 million, a PE ratio of -6.38 and a beta of 1.70. The business’s 50-day moving average price is $0.99 and its two-hundred day moving average price is $1.03.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The firm had revenue of $18.35 million during the quarter, compared to the consensus estimate of $18.58 million. Rockwell Medical had a negative net margin of 7.67% and a negative return on equity of 15.64%.

Hedge Funds Weigh In On Rockwell Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Panagora Asset Management Inc. acquired a new stake in shares of Rockwell Medical in the 2nd quarter valued at about $41,000. XTX Topco Ltd lifted its holdings in shares of Rockwell Medical by 286.5% in the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after purchasing an additional 46,029 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Rockwell Medical during the fourth quarter worth about $84,000. GSA Capital Partners LLP grew its holdings in shares of Rockwell Medical by 635.1% during the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after buying an additional 141,672 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Rockwell Medical by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after buying an additional 41,668 shares in the last quarter. 23.31% of the stock is owned by institutional investors and hedge funds.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.